News coverage about BioScrip (NASDAQ:BIOS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioScrip earned a news impact score of 0.12 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1018705584973 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of BioScrip (NASDAQ BIOS) opened at $3.00 on Friday. BioScrip has a 52 week low of $1.21 and a 52 week high of $3.39. The company has a market cap of $381.27, a price-to-earnings ratio of -4.41 and a beta of 0.27. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.
BioScrip (NASDAQ:BIOS) last released its earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million for the quarter, compared to the consensus estimate of $202.91 million. During the same period in the previous year, the business earned ($0.12) EPS. The business’s revenue for the quarter was down 11.5% on a year-over-year basis. equities research analysts expect that BioScrip will post -0.63 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on BIOS. Zacks Investment Research upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. BidaskClub upgraded shares of BioScrip from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. SunTrust Banks set a $4.00 price target on shares of BioScrip and gave the stock a “buy” rating in a research note on Thursday, December 21st. Finally, ValuEngine upgraded shares of BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, November 30th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. BioScrip presently has an average rating of “Buy” and a consensus target price of $3.63.
In other news, CEO Daniel E. Greenleaf bought 15,000 shares of BioScrip stock in a transaction dated Thursday, November 9th. The stock was bought at an average price of $2.03 per share, for a total transaction of $30,450.00. Following the purchase, the chief executive officer now owns 31,000 shares of the company’s stock, valued at $62,930. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.80% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/20/bioscrip-bios-given-news-sentiment-rating-of-0-12-updated.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioScrip and related companies with MarketBeat.com’s FREE daily email newsletter.